Background {#Sec1}
==========

Cervical cancer is the second most fatal cancer for women in Mexico \[[@CR1]\]. Chronic infection with high-risk human papillomavirus (hrHPV), one of the world's most prevalent sexually transmitted infections (STIs), is a necessary cause of cervical cancer \[[@CR2]\]. Over 100 types of HPV have been established. Among these, 15 HPV types are classified as carcinogenic or high risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) \[[@CR3]\]. From the point of view of cervical pathology, however, two types---HPV16 and 18---account for the vast majority of cervical cancer cases. Worldwide, HPV16 alone accounts for almost 60 % of cases, and HPV18 accounts for another 10 % of cases \[[@CR4]\].

Because many countries in the developing world including Mexico do not have reliable cancer registries, it is difficult to ascertain the incidence of disease. Without incidence rates, resource allocation cannot fully reflect the differing needs of the various health districts. The prevalence of hrHPV, particularly HPV16 and HPV18, can be used as a valuable predictor of cervical cancer incidence \[[@CR5]\].

Wise resource allocation will become more important as the cervical cancer prevention landscape in Mexico shifts. In 2008, Mexico began using hrHPV testing instead of cervical cytology for primary screening in the public sector, and then in 2012, Mexico introduced a universal HPV vaccination program for all girls in the 5^th^ grade of elementary school \[[@CR6]\]. The impact of the vaccine, however, will not be seen for at least a generation, and therefore, research groups in Mexico and throughout the developing world are seeking to establish their cervical cancer screening program. At the current time, Mexican health services cannot support a screening program in which all hrHPV positive women are sent for further diagnostic work-up \[[@CR7]\]. Indeed only a small percentage of hrHPV positive women will actually ever develop high grade cervical intraepithelial neoplasia (CIN) \[[@CR8]\].

To avoid overburdening the local services, researchers are now working to identify a reliable triage testing strategy for hrHPV positive women. While cytology seems to be an obvious triage option given the existing infrastructure, we are also trying alternatives because of the difficulty of maintaining high-quality cytology in Mexico \[[@CR9]\]. One potentially important option for the triage of hrHPV positive women would be to identify those positive for HPV16 and HPV18 for further evaluation and diagnostic confirmation. Results of the Roche ATHENA trial in the US demonstrate the strong promise of HPV16/18 based triage strategies to increase diagnostic efficiency without sacrificing sensitivity of disease detection \[[@CR10]\]. Indeed Roche has recently received FDA approval for its test to triage HPV16/18 positive women for diagnostic follow-up. The feasibility of a similar screening strategy in Mexico will rest on the prevalence of HPV16 and HPV18 and the positive predictive value of these types for high grade CIN.

The prevalence of HPV16 and HPV18 within the general population has not been well described in Mexico. The last population-based study to report on the prevalence of HPV16 and HPV18 in Mexico was published over a decade ago in 2001 \[[@CR11]\]. More recent studies have only looked at small convenience samples \[[@CR12]--[@CR14]\]. The present study is part of a larger study, FRIDA (Forwarding Research for Improved Detection and Access), a population-based demonstration project designed to evaluate the performance and cost-effectiveness of triage alternatives for cervical cancer screening in Tlaxcala, Mexico. While a number of small studies have reported on the type-specific prevalence of HPV16 and HPV18 in Mexico \[[@CR11]--[@CR18]\], the present study is the largest to do so with population-based representation.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We studied specimens and data from the FRIDA study, an on-going population-based demonstration project that began in Tlaxcala, Mexico in August 2013. Women 30 to 64 years of age living within our target health district in Tlaxcala, Mexico are being recruited directly by healthcare personnel within preventive, family planning and gynecological health services during routine visits. This target health district includes approximately 100 health care facilities. The complete FRIDA cohort is projected to include more than 80% of the target population of over 100,000 women aged 30 to 64 years. Although the Tlaxcala cervical cancer screening program continuously invites women for screening at regular time intervals, women are generally tested opportunistically, with screening usually being initiated by the woman herself. This preliminary analysis includes results from the first 31,629 women enrolled in the demonstration project who came to the the clinic health care settings. Women then were invited at the clinic into the study. Women who were pregnant or had had a hysterectomy were excluded, leaving a total of 30,829 women in the present analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow Chart of hrHPV Screening of the FRIDA Study Population. Women 30 to 64 years of age living within our target health district were invited by healthcare personnel. This study reports the results from the first 31,629 women who volunteered to participate in the Tlaxcala cervical cancer screening program. Four-hundred and eighty-three women were excluded, leaving 30,829 who had hrHPV results available, in the current analysis. Of those 30,829 women, 3,401 women were positive for hrHPV. Among those 3,401 women, 13.6 % were positive for HPV16, 5.9 % for HPV18 and 1.1 % for both HPV16 and HPV18 coinfection. These three categories indicate positivity independent of the presence of other hrHPV types. The last category of other high risk HPV types include women who tested positive for other hrHPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), but neither HPV16 nor HPV18

The study proposal was reviewed and approved by the research and ethics committees of the Instituto Nacional de Salud Pública (INSP) (1094), Comisión Federal para la Protección Contra Riesgos Sanitarios (CAS/OR/01/CAS/123300410C0044-3578/2012) and Secretaría de Salud del Estado de Tlaxcala (SS. DECI-OI-13/12). The purpose and procedures of the study were explained to all participants and informed verbal consent was obtained.

Procedures {#Sec4}
----------

Health care personnel conducted face-to-face interviews of FRIDA study participants using pre-printed pen and paper surveys designed to elicit details of sexual behavior, history of STIs, parity, gynecologic and reproductive health histories, and other probable risk factors for cervical cancer.

Participants were then given a pelvic exam during which a cervical sample was collected using a Cervex-Brush® (Rovers®). This cervical sample was placed in a ThinPrep® vial (Hologic, Inc., Bedford, MA) and then 0.4 mL tested for hrHPV using Roche's cobas® 4800 system. This assay uses a PCR-based in-vitro test for the simultaneous detection of 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in liquid based cervical samples. The system detects HPV16 and HPV18 individually, and the remaining 12 hrHPV genotypes as a pool \[[@CR19]\]. The testing was carried out at the HPV laboratory at the INSP in Cuernavaca, Mexico according to manufacturer's instructions (Roche Diagnostics).

Statistical analysis {#Sec5}
--------------------

Descriptive statistics were used to characterize the variables. Age, age of sexual debut, parity, and number of sexual partners were recorded as continuous, numeric variables, and then analyzed as categorical variables. Marital status, use of contraception (hormonal, IUD, condoms), history of previous STIs, and smoking history were both collected and analyzed as categorical variables. In the analysis, participants classified as hrHPV positive tested positive for any of the 14 hrHPV types including HPV16 and HPV18. Among these positives, participants were then classified as positive for HPV16 regardless of whether or not they also tested positive for another hrHPV type. Participants classified as positive for HPV18 were treated in the same way. The designation "HPV16/18" refers to participants who tested positive for either HPV16, HPV18, or both, regardless of other hrHPV types. The designation "HPV16/18 only" means these participants tested positive for HPV16 and/or HPV18, but no other hrHPV types. The "non-16/18 hrHPV only" group refers to women who tested positive for other hrHPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), but neither HPV16 nor HPV18. The "HPV16/18 and other hrHPV types" group tested positive for HPV16 and/or HPV18 as well as another hrHPV type.

All pooled hrHPV, HPV16/18 only, non-16/18 hrHPV only, and HPV16/18 and other hrHPV type prevalence were estimated by age along with associated binomial 95 % confidence intervals (CI). Looking at the prevalence graphs by age categories, we decided to use a quadratic model for log odds as a function of age. Assuming that the quadratic models are approximately correct, the coefficient on age^2^ is a rough measure of the steepness of the parabola. A formal test for differences in steepness of curves for different hrHPV categories was constructed by using the coefficient estimates and their standard errors. Because the sample sizes are large, a normal approximation was used.

We furthermore used logistic regression to compute odds ratios (ORs) with 95 % CIs to identify independent risk factors for hrHPV infections. ORs were adjusted for age to account for differences in age-group prevalence and for comparability with other population reports. Variables associated with hrHPV infections were adjusted for other covariates using multiple logistic regression analysis. Data analysis was conducted using STATA version 12.0 (StataCorp). A two-sided significance level of 0.05 was chosen to indicate statistical significance.

Results {#Sec6}
=======

Characteristics of the population {#Sec7}
---------------------------------

Nearly 97% of women who volunteered to participate in the Tlaxcala cervical cancer screening program met the inclusion study criteria. Approximately 31 % of the target population is included in this analysis. The distribution of ages screened does not perfectly reflect the target population. A higher proportion of women aged 30 to 49 were screened than older groups in the population. Approximately 3.4 % of women aged 60 to 64 were screened. The mean age of the study population was 41.8 years (data not shown).

Approximately 90 % of participants were married, and nearly two-thirds of participants were 18 or older when they initiated sexual activity. The majority of participants have been pregnant and almost 50 % report 3 or more live births. The vast majority of the study participants reported one lifetime sexual partner (71 %). A history of oral contraceptive use was reported by about 21 % of women and a little more than one-third (33 %) were using an IUD. Most women (83 %) reported not using a condom at all in the last 12 months. Histories of previous sexually transmitted infections were rare (3 %), and about 3 % of women reported ever having smoked (Table [1](#Tab1){ref-type="table"}). Approximately 5.0 % self-reported a history of abnormal cervical cytology (data not shown) and 24.9 % of those women received treatment.Table 1Associations between hrHPV and Reproductive Health and Behavior Variablesn (% of Total pop. screened)hrHPV nPrevalence hrHPV (95 % CI)Age Adjusted OR (95 % CI)^a^Multivariate Adjusted OR (95 % CI)^b^Age (years)30--347,083 (23.0)97113.7 (12.9--14.5)**1.65 (1.46--1.87)1.61 (1.42--1.83)**35--397,131 (23.1)80911.3 (10.6--12.1)**1.33 (1.17--1.51)1.31 (1.15--1.49)**40--446,176 (20.0)5829.4 (8.7--10.2)1.08 (0.95--1.24)1.09 (0.95--1.25)45--494,402 (14.3)3868.8 (7.9--9.6)1 (ref)1 (ref)50--542,969 (9.6)30410.2 (9.2--11.4)1.19 (1.01--1.39)1.19 (1.01--1.40)55--592,015 (6.5)23011.4 (10.1--12.9)**1.34 (1.28--1.59)1.32 (1.11--1.58)**60--641,053 (3.4)11911.3 (9.5--13.4)**1.33 (1.07--1.65)1.34 (1.07--1.68)**Total30,829340111.0 (10.7--11.4)Marital StatusUnmarried3, 362 (10.9)60017.9 (16.6--19.2)**1.96 (1.78--2.16)1.65 (1.48--1.83)**Married/Civil Union27,467 (89.1)2,80110.2 (9.8--10.6)1 (ref)1 (ref)Age of Sexual Debut≤1711,221 (36.4)1,33311.9 (11.3--12.5)**1.13 (1.05--1.20)**1.04 (0.97--1.13)≥1819,591 (63.6)2,06710.6 (10.1--11.0)1 (ref)1 (ref)Number of Lifetime Sexual Partners^c^1 partner21,832 (70.8)1,9508.9 (8.6--9.3)1 (ref)1 (ref)2 partners5,910 (19.2)87914.9 (14.0--15.8)**1.77 (1.62--1.93)1.61 (1.47--1.76)**≥3 partners2,940 (9.5)55618.9 (17.5--20.4)**2.34 (2.11--2.59)1.96 (1.75--2.19)**Number of Sexual Partners in the Last 12 Months^c^0 partners5,724 (18.6)68612.0 (11.2--12.9)1 (ref)1 (ref)1 partner24,792 (78.2)2,65910.7 (10.3--11.1)0.87 (0.79--0.95)0.96 (0.87--1.05)≥2 partners111 (0.4)3228.8 (21.2--37.9)**2.9 (1.90--4.41)1.75 (1.13--2.70)**Parity07,091 (23.1)78511.1 (10.4--11.8)1 (ref)1 or 28,511 (27.6)96711.4 (10.7--12.1)1.04 (0.94--1.15)3 or more15,049 (48.8)1,63110.8 (10.4--11.3)1.05 (0.96--1.16)History of Hormonal ContraceptionYes6,417 (20.8)79012.3 (11.5--13.1)**1.17 (1.07--1.27)**1.10 (1.01--1.20)No24,154 (78.1)2,58710.7 (10.3--11.1)1 (ref)1 (ref)Current IUD UseYes10,170 (33.0)1,16411.5 (10.8--12.1)1.05 (0.98--1.14)No19,887 (64.5)2,15310.8 (10.4--11.3)1 (ref)Condom Use in the last 12 monthsNever25,557 (82.9)2,68210.5 (10.1--10.9)1 (ref)1 (ref)Almost always2,777 (9.0)37313.4 (12.2--14.8)**1.27 (1.13--1.43)**1.15 (1.01--1.29)Always1,716 (5.6)25314.7 (13.1--16.5)**1.42 (1.23--1.63)1.26 (1.09--1.46)**History of a Previous STIYes979 (3.2)18218.6 (16.3--21.1)**1.91 (1.62--2.25)1.54 (1.30--1.84)**No29,424 (95.4)3,16110.7 (10.4--11.1)1 (ref)1 (ref)Tobacco UseNever29,238 (94.8)3,16010.8 (10.5--11.2)1 (ref)1 (ref)Ever964 (3.1)17518.2 (15.8--20.7)**1.77 (1.49--2.10)1.23 (1.03--1.47)***Abbreviations*: *STI* sexually transmitted infections, *OR* odds ratio, *CI* confidence interval^a^Odds ratios for all the variables with the exception of age itself are adjusted for age. Age was included in the model as a categorical variable (30--34, 35--39, 40--44, 45--49, 50--54, 55--59, 60--64); ^b^Association test was adjusted for age, marital status, age of sexual debut, number of lifetime sexual partners, number of sexual partners in the last 12 months, history of hormonal contraception, condom use in the last 12 months, history of a previous STI, and tobacco use; ^c^Women who reported zero lifetime sexual partners were excludedStatistically significant *p* values ≤ 0.05 of the OR\'s are marked in bold font

High risk HPV prevalence and risk profile {#Sec8}
-----------------------------------------

The estimated overall prevalence of hrHPV in this population was 11.0 % (95 % CI 10.7--11.4). High risk HPV DNA was detected in 13.7 % (95 % CI 12.9--14.5) of women aged 30 to 34 and in 11.3 % (95 % CI 10.6--12.1) of women aged 35 to 39. The prevalence estimates declined to 9.4 % (95 % CI 8.7--10.2), 8.8 % (95 % CI 7.9--9.6), and 10.2 % (95 % CI 9.2--11.4) for women aged 40--44, 45--49, and 50--54, respectively. High risk HPV detection then increased again to 11.4 % (95 % CI 10.1--12.9) and 11.3 % (95 % CI 9.5--13.4) for women aged 55 to 59 and 60 to 64, respectively (Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). In the multivariate model, women aged 30 to 39 were at higher risk of hrHPV infection than women aged 45 to 49, the reference group. The prevalence of hrHPV infections for the oldest age group, women aged 55 to 64, was also significantly different than the reference group, showing a clear U-shaped curve. The coefficients on age^2^ were significant.Fig. 2Age Specific Prevalence of hrHPV and HPV16/18 with 95 % CI. The overall prevalence of hrHPV was 11.0 % in this population. Two percent of women overall were positive for HPV16 and/or HPV18 (HPV16/18). The prevalence of hrHPV overall and HPV16/18 by age group both show a bimodal distribution with an increased prevalence for the youngest women in the population aged 30--39 and a second bump of positivity for the oldest women aged 60 and above

In addition to age related risks, being unmarried, having a history of oral contraceptive use, having a history of smoking, condom use, having more than one lifetime sexual partner, having two or more sexual partners in the last year, and a history of another STI were also found to be positively associated with hrHPV infections in the multivariate model (p \< 0.05). This model adjusted for marital status, age at initiation of sexual intercourse, number of lifetime sexual partners, number of sexual partners in the last 12 months, history of hormonal contraception, condom use in the last 12 months, a history of a previous STI, and tobacco use. Age of sexual initiation was, significant only in the age adjusted model (Table [1](#Tab1){ref-type="table"}).

Prevalence of hrHPV Infections by Type in the total screened population {#Sec9}
-----------------------------------------------------------------------

Among all age groups, 9.0 % tested positive for non-16/18 hrHPV only. The distribution by age group showed a U-shaped curve with increased prevalence estimates for women in their 30s and as well as for women over the age of 50 (Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). The coefficients on age^2^ were significant (Table [3](#Tab3){ref-type="table"}).Table 2Type Specific Prevalence of hrHPV by AgeAge (years)Total pop.HPV16/18^a^Non-16/18 hrHPV onlyHPV16/18 onlyHPV16/18 andNon-16/18 hrHPV% (95 % CI)% (95 % CI)% (95 % CI)% (95 % CI)30--347,0832.9 (2.5--3.3)10.8 (10.1--11.5)1.8 (1.5--2.2)1.1 (0.9--1.4)35--397,1312.3 (2.0--2.7)9.1 (8.4--9.7)1.5 (1.2--1.8)0.8 (0.6--1.1)40--446,1761.8 (1.5--2.1)7.7 (7.0--8.3)1.3 (1.0--1.6)0.5 (0.3--0.7)45--494,4021.3 (1.0--1.6)7.5 (6.8--8.3)0.8 (0.6--1.2)0.4 (0.3--0.7)50--542,9691.4 (1.0--1.8)8.9 (7.9--10.0)0.6 (0.4--1.0)0.7 (0.5--1.1)55--592,0151.5 (1.1--2.2)9.9 (8.6--11.3)0.9 (0.6--1.5)0.6 (0.3--1.0)60--6410532.2 (1.5--3.3)9.1 (7.5--11.0)1.1 (0.7--2.0)1.0 (0.6--1.9)Total30,8292.0 (1.9--2.2)9.0 (8.7--9.3)1.3 (1.2--1.4)0.7 (0.6--0.8)*Abbreviations*: *CI* confidence interval^a^HPV16/18 refers to women who are positive for HPV16 and/or 18 regardless of other hrHPV types for which they may or may not test positivFig. 3Age Specific Prevalence of hrHPV Types with 95 % CI. The cobas® 4800 system delivers hrHPV results in three categories: HPV16, HPV18, and other hrHPV. Based on these results, we divided the population into three mutually exclusive categories: (1) women positive for only other hrHPV (non-16/18 hrHPV only), (2) women positive for HPV16 and/or HPV18 (HPV16/18), and (3) women positive for HPV16 and/18 as well as another hrHPV (HPV16/18 + other hrHPV). The prevalence of these three categories by age group shows a similar bimodal distribution with increased prevalence values for the youngest and oldest women in the populationTable 3Quadratic Model for Log Odds of hrHPV and hrHPV by TypeCoef. on age^2^ (SD)Coef. on age (SD)Model *p* valueTwo-tailed P values for Differences in Coefficient on Age^2^Any hrHPV0.00178 (0.000299)−0.1702 (0.0204)\<0.001HPV16/18^a^0.00228 (0.000520)−0.2302 (0.0458)\<0.0010.206^b^Non-16/18 hrHPV only0.00155 (0.000250)−0.1449 (0.0223)\<0.001HPV16/18 only0.00147 (0.000681)−0.1628 (0.0594)0.0311.098^c^HPV16/18 and other hrHPV0.00342 (0.000805)−0.3246 (0.0717)\<0.001*Abbreviation*: *SD* standard deviation^a^HPV16/18 refers to women who are positive for HPV16 and/or 18 regardless of other hrHPV types for which they may or may not test positive; ^b^comparison non-16/18 hrHPV only vs HPV16/18; ^c^ comparison non-16/18 hrHPV only vs HPV16/18 only

Among all age groups, 1.5 and 0.7 % were positive at least for HPV16 and HPV18, respectively. By age group, the prevalence of HPV16/18 was highest for the youngest women in the population at 2.9 % (95 % CI 2.5--3.3) for ages 30--34 and 2.3 % (95 % CI 2.0--2.7) for ages 35--39. Prevalence estimates then declined to 1.8 % (95 % CI 1.5--2.1), 1.3 % (95 % CI 1.0--1.6), 1.4 % (95 % CI 1.0--1.8), and 1.5 % (95 % CI 1.1--2.2) for ages 40--44, 45--49, 50--54, and 55--59 (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). Estimates then surge for women aged 60 to 64 to 2.2 % (95 % CI 1.5--3.3) (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). The prevalence of HPV16 and HPV18 coinfection but neither hrHPV types was rare (0.08 %) (data not shown). The distribution by age group for women who only had HPV16/18 infections showed a marked U-shaped curve with an initial increase for women in their 30s, a decreased prevalence for women in their 40s and 50s, and a second increase in prevalence for women in their 60s (Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Like the other prevalence curves, the coefficients on age^2^ for HPV16/18 only infections is highly significant (Table [3](#Tab3){ref-type="table"}).

Finally, the prevalence of coinfections with HPV16/18 and another hrHPV type was 0.7 %. The prevalence by age showed a similar U-shaped curve with increased estimates for the younger and older women in the population (Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Again, this curve had a significant quadratic trend (Table [3](#Tab3){ref-type="table"}). Overall, there was no significant difference between the quadratic terms for HPV16/18 and the non-16/18 hrHPV only curve. Furthermore, when the quadratic terms for HPV16/18 only and non-16/18 hrHPV only were compared, there was no significant difference (*p* \< 0.05) (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec10}
==========

Our population-wide investigation provides a better representation of exposure to infection than a clinic-based population with abnormal cytology in whom HPV16 and HPV18 would be over-represented. The present study is not only the largest in Latin America and most current population based study to date, but is also the first to use Roche's cobas® 4800 system for hrHPV analysis. Roche's cobas® 4800 system has been shown to be a highly sensitive and specific test for the detection of hrHPV as well as HPV16 and HPV18 \[[@CR20]\].

There has only been one other previous large population based study conducted in Mexico to report hrHPV type specific prevalence estimates. Although this previous study used a different design and methodology, the age distribution of hrHPV from this study shows a similar U-shaped curve with a first peak for the youngest women and a second peak for the oldest age group \[[@CR11]\]. A similar U-shaped curve was found in both the Guanacaste cohort in Costa Rica \[[@CR21]\] and a population of Colombian women \[[@CR22]\]. Outside of Latin America, a meta-analysis of worldwide epidemiologic data also found this same U-shaped curve for developing nations throughout the world including Africa and Southeast Asia \[[@CR23]\].

While the second peak of HPV infections for women up to ages 30 to 39 has been seen in diverse populations throughout the world \[[@CR23], [@CR24]\], in Central and South America this peak appears to be more prominent. Epidemiologic data suggests that this first peak of infection can be correlated with sexual initiation in younger women when they are exposed to HPV for the first time and their adaptive immune response has yet to develop \[[@CR8]\].

The second peak of infections for women ages 60 to 64 in the FRIDA population is again only seen mirrored in populations throughout the developing world. In North America and throughout most of Europe, the prevalence of HPV infection declines consistently after the initial peak associated with sexual debut \[[@CR23]\]. The reasons for this second peak of hrHPV DNA detection are unknown. Current theories suggest that this second peak may be the result of immune depression leading to reactivation of previous quiescent infections \[[@CR25], [@CR26]\], the acquisition of new hrHPV infections through changes in sexual behavior on the part of the women themselves and/or their partners, or a cohort effect \[[@CR25], [@CR27]--[@CR29]\]. Another theory suggests that differences in screening programs may also play a role in the presence of this second peak. In countries with effective screening programs, the removal of precancerous lesions is believed to have an antigen-presenting effect to the immune system that may help protect against future HPV infections \[[@CR30]\]. Based on this theory, in countries where screening programs do not identify and treat these precancerous lesions, women cannot benefit from this added immunologic boost.

For the FRIDA population, the U-shaped prevalence curve was also seen for HPV16/18 infections. This same pattern is seen in the Guanacaste cohort in Costa Rica \[[@CR21]\] and in the previous Mexican study for HPV16, but not for HPV18 \[[@CR11]\]. Overall, point estimates of HPV16/18 prevalence appear higher in other study populations throughout Latin America \[[@CR9], [@CR21], [@CR23], [@CR31]\], but due to different study designs, it is difficult to draw conclusions concerning the comparative burden of infections.

In addition to the differences seen among age groups, multiple sexual partners was found to be a risk factor for hrHPV infection. Other studies have found a similar association between an increased number of sexual partners and risk of hrHPV infection \[[@CR26], [@CR32], [@CR33]\]. In contrast, age at first intercourse was not found to be an independent risk factor for hrHPV in this population, similar to other studies. However, we also acknowledge that there are previous studies reporting that the age of sexual debut is an independent risk factor by itself \[[@CR34]\]. It should be noted that a particularity of FRIDA population was a younger age of sexual debut was highly correlated with having more than one lifetime sexual partner (*p* \< 0.001) (data not shown).

This preliminary analysis only contains 30 % of the target population. With a larger population, our study will be better powered to describe HPV16/18 determinants. We furthermore acknowledge the possibility of social desirability bias with the sensitive, self-reported data, such a bias may have led to underestimation of certain risk factors. We attempted to limit such bias by providing a private space for the recruitment interviews.

In the absence of cervical screening or cancer registries in Mexico at the national, regional or state levels, these prevalence data can help to better inform resource allocation decisions. Sharma et al. developed a model whereby hrHPV prevalence data can be used to estimate cervical cancer risk \[[@CR5]\]. While Sharma et al.'s models have been developed to predict cervical cancer incidence in developed countries, more data is needed in developing countries such as Mexico to refine these models so they can be better applied in the developing world \[[@CR5]\]. Such a reliable model to determine cervical cancer risk would be a very valuable tool in Mexico and through the developing world. Nonetheless, it is important to note that the generalizability of the findings may be limited both within Mexico and outside of Mexico.

Beyond predicting cervical cancer risk, the prevalence data from this study can serve a number of additional uses from a policy perspective. First the prevalence information can be useful for evaluating the impact of HPV vaccination over the long term. While a number of surrogate endpoints of vaccine impact may be used, HPV type-specific prevalence data has become the standard early indicator of choice \[[@CR35], [@CR36]\], and thus these prevalence data may also be used as baseline to monitor vaccine effectiveness.

This prevalence information will furthermore be useful for policymakers trying to determine the best triage practices in Mexico. In 2013, our study group was able to show that primary screening for hrHPV is effective, but a secondary follow-up or triage test is needed to determine which women should be sent to colposcopy \[[@CR7]\]. We attempted to send all hrHPV positive women to colposcopy, but found it was not only inefficient, but also overburdened the local health services. In this previous pilot, we sent nearly 11 % of women for colposcopy services. If we had triaged women based on HPV16/18, we would have only sent 2 % of women and still detected more than 70 % of disease \[[@CR4]\]. Furthermore, some analyses suggest that the best alternative may be a combination of triage alternatives to offer high joint specificity to detect CIN2 or more, including other triage tests such as cytology, p16 or DNA methylation or at least evidence of 6 to 12 months of persistent hrHPV infection before referral \[[@CR37]\]. A triage algorithm using HPV16/18 testing has been validated in the US \[[@CR10]\], but needs to be further explored in Mexico. This prevalence data will help policymakers to determine whether or not the current infrastructure in Mexico can support the triage of HPV16 and HPV18 positive women. Further study is still needed to determine the performance and cost-effectiveness of HPV16 and HPV18 detection as an additional triage alternative for hrHPV positive women, and what additional testing may be required to ensure a more effective and safe cervical cancer screening program in Mexico.

The main strength of our study is our large, population-based approach. This is the first study in Mexico of this size to assess the prevalence of HPV16/18. This epidemiologic data will contribute to the creation of a more reliable strategy of cervical cancer prevention in Mexico.

Conclusion {#Sec11}
==========

This sub-analysis of the FRIDA study demonstrates the population level prevalence pattern of hrHPV and HPV16/18 by age in Mexico. Both hrHPV and HPV16/18 positivity have a bimodal distribution by age with higher prevalences at ages 30--39 and 60--64. Infections with hrHPV were also found to be positively associated with an increased number of lifetime sexual partners, a history of STIs, being unmarried, use of hormonal contraception, and reported condom use. Our results set the stage for an improved cervical cancer screening strategy in Mexico. While primary screening for hrHPV has already been instituted in Mexico, this prevalence data suggests the feasibility of HPV typing as an additional screening parameter nationwide.
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CIN

:   Cervical intraepithelial neoplasia
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HPV

:   Human papillomavirus
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:   high-risk human papillomavirus
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:   Intrauterine device
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:   Odds ratios
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:   Sexually transmitted infections

Drs. Heidi Bauer, Karen Sokal-Gutierrez, and Maureen Lahiff helped to review the manuscript, and Dr. Lahiff and Dr. Ndola Prata further provided biostatistical support. The authors would also like to recognize the FRIDA study population for their generous participation as well as the Tlaxcala FRIDA field team for collecting the data and supervising field procedures.

\*FRIDA Study Group: Samantha E. Rudolph, Attila Lorincz, Cosette Wheeler, Patti Gravitt, Eduardo Lazcano, Leticia Torres-Ibarra, Leith León, Paula Ramírez, Berenice Rivera, Eduardo L. Franco, Jack Cuzick, Pablo Méndez, Jorge Salmerón, Mauricio Hernández, Thomas C. Wright, Anna Barbara Moscicki, Yvonne Flores, Mark H. Stoler, Enrique Carmona, Kathleen M. Schmeler, David Bishai, Pilar Hernández, Daniel Alvarez, Elizabeth Barrios, Rubi Hernández, Indira Mendiola, and Vicente González.

Funding {#FPar1}
=======

This study was supported by the National Institute of Public Health of Mexico, the Coordinación de Investigación en Salud del Instituto Mexicano del Seguro Social, the Secretaría de Salud Tlaxcala, the Instituto Nacional de las Mujeres, and the Consejo Nacional de Ciencia y Tecnología \[FOSISS 2013 202468\]. Additional support has been provided by Roche Diagnostics, BD Diagnostics, DICIPA and Arbor Vita Corporation. The study sponsors did not played a role in designing the study, collecting, analyzing or interpreting the data, writing the report, or submitting this paper for publication. UC Berkeley Center for Global Public Health, Schoeneman Grant, Joint Medical Program Thesis Grant, and Cancer Research UK (C569/A10404).

Availability of data and materials {#FPar2}
==================================

The datasets generated during and/or analysed during the current study are not publicly available due to protecting participant confidentiality but are available from the corresponding author on reasonable request.

Authors' contributions {#FPar3}
======================

SR, AL, CW, PG, ELP, LTI, EF, JC and JS were responsible for the study design and had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JS, BR, PMH, LLM, LTI site investigators, contributed to study implementation and study coordination. BR, PR, LLM, LTI, RH and JS were responsible for the data collection and study supervision. SR, AL, CW, PG, LTI, ELP, JC and JS were responsible of drafting the manuscript and contributed to data interpretation. SR, RH and JC performed and reviewed the statistical analyses. All authors contributed ideas to the manuscript, provided critical revision of content, and approved the final version.

Competing interests {#FPar4}
===================

JS has received funding for research projects from Qiagen, GSK, Merck, Roche, Beckton Dickinson, Gen-Probe, DICIPA and Arbor Vita. ATL is a consultant for EVE Medical. CMW has received funding through the University of New Mexico for HPV vaccine studies (Merck and GSK) and reagents and equipment for HPV genotyping (Roche Molecular Systems).

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

The study proposal was reviewed and approved by the research and ethics committees of the Instituto Nacional de Salud Pública (INSP) (1094), Comisión Federal para la Protección Contra Riesgos Sanitarios (CAS/OR/01/CAS/123300410C0044-3578/2012) and Secretaría de Salud del Estado de Tlaxcala (SS.DECI-OI-13/12). The purpose and procedures of the study were explained to all participants and informed verbal consent was obtained.
